Search clinical trials for: Pembrolizumab, Eftilagimod alpha

Total 9277 results

Regeneron Pharmaceuticals

Recruiting

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Melanoma

United States, Spain, Germany, Mexico, Turkey, Canada, Austria, Netherlands, United Kingdom, Italy, Georgia, France, Brazil, Romania, Czechia, Argentina, Australia, Ireland, Chile, Hungary, South Africa, Belgium, Poland, Peru
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Metastatic Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Androgen Receptor Positive

United States
OHSU Knight Cancer Institute
Merck Sharp & Dohme LLC; Oregon Health and Science University; Collins Medical...

Active, not recruiting

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

Castration-Resistant Prostate Carcinoma | Recurrent Prostate Carcinoma | PSA Progression | Hormone-Resistant Prostate Cancer | Stage IV Prostate Adenocarcinoma Cancer AJCC v8

United States
Case Comprehensive Cancer Center

Recruiting

Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)

Glioblastoma, Adult

United States
MedSIR
Merck Sharp & Dohme LLC

Active, not recruiting

Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents (PECATI)

Metastatic Thymic Carcinoma | Thymoma Type B3

Spain, France, Italy
Roswell Park Cancer Institute
Merck Sharp & Dohme LLC

Withdrawn

Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Refractory Colorectal Adenocarcinoma | Microsatellite Stable | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA... and other conditions

United States
Jair Bar, M.D., Ph.D.
Merck Sharp & Dohme LLC

Completed

Anti PD-1 Neo-adjuvant Treatment for NSCLC (MK3475-223)

Non Small Cell Lung Carcinoma | Stage II | Stage I

Israel
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)

Urothelial Cancer
Merck Sharp & Dohme LLC

Completed

Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)

Head and Neck Squamous Cell Carcinoma
Merck Sharp & Dohme LLC

Terminated

Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)

Advanced Melanoma

United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Harbour BioMed (Guangzhou) Co. Ltd.

Not yet recruiting

A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody

Solid Tumor
Silverback Therapeutics

Active, not recruiting

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

HER2 Positive Solid Tumors

United States, Korea, Republic of, Australia
Baptist Health South Florida
Merck Sharp & Dohme LLC; Miami Cancer Institute

Completed

Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors

Solid Tumor, Adult

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Recurrent Glioblastoma

Recurrent Glioblastoma | Recurrent Gliosarcoma

United States
National University Hospital, Singapore
Merck Sharp & Dohme LLC; Adagene Inc

Recruiting

Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer (ComPACT)

Triple Negative Breast Cancer | Advanced Solid Tumor

Singapore
Peking Union Medical College Hospital

Completed

Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors

Cholangiocarcinoma | Biomarker | Combinational Immunotherapy | Liver Neoplasm Malignant Primary

China
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC; Institute of Cancer Research, United Kingdom; National...

Recruiting

Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer (PLUMMB)

Invasive Bladder Cancer

United Kingdom
QBiotics Group Limited
Merck Sharp & Dohme LLC

Terminated

A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma

Melanoma

Australia
Lawrence Feldman, MD
Merck Sharp & Dohme LLC; HiberCell, Inc.

Active, not recruiting

Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

Non-Small Cell Lung Cancer

United States
4SC AG

Completed

4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy (SENSITIZE)

Malignant Melanoma

Germany, Italy
Adaptimmune

Withdrawn

SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer

Head and Neck Cancer

United States
Amphivena Therapeutics, Inc.

Completed

Study of AMV564 in Patients With AML

Acute Myeloid Leukemia

United States
Southern Illinois University
Merck Sharp & Dohme LLC

Active, not recruiting

MK-3475/BCG in High Risk Superficial Bladder Cancer (MARC)

Bladder Cancer

United States
Sun Yat-sen University

Unknown

A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma

Renal Cancer Metastatic

China
Monopteros Therapeutics Inc.

Recruiting

A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Metastatic Cancer | Advanced Solid Tumor | Advanced Cancer | Solid Tumor, Adult | Refractory Cancer

United States
Samsung Medical Center

Recruiting

Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer

Gastric Cancer

Korea, Republic of
PharmAbcine

Active, not recruiting

TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma

Recurrent Glioblastoma

Australia
Wakayama Medical University
Merck Sharp & Dohme LLC

Unknown

Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer

Small Cell Lung Cancer Extensive Stage

Japan
University of California, Los Angeles

Completed

Effectiveness of CES on Emotional and Cellular Wellbeing

Depression | Anxiety

United States
Shanghai Minimally Invasive Surgery Center

Recruiting

Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen

Gastric Cancer Stage IIIB-IIIC

China
Yonsei University

Not yet recruiting

Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma

Soft Tissue Sarcoma
Stanford University
Merck Sharp & Dohme LLC

Recruiting

Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

Thyroid Cancer

United States
Henry Ford Health System

Recruiting

HFHS-1801-A Pilot Study of Immunotherapy as Consolidation Therapy for Patients With Recurrent Head and Neck Cancer

Head and Neck Neoplasms

United States
Sanford Health
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab in Combination With CRT for LA-SCCHN

Head and Neck Cancer | Laryngeal Cancer | Oropharynx Cancer | Oral Cavity Cancer | Larynx Cancer | Squamous Cell Carcinoma | Hypopharynx Cancer

United States
CG Oncology, Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin (CORE-001)

Non Muscle Invasive Bladder Cancer

United States, Korea, Republic of
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)

rrCLL | rrMM | rrDLBCL
University of Erlangen-Nürnberg Medical School

Active, not recruiting

Radiotherapy With Pembrolizumab in Metastatic HNSCC

Head and Neck Squamous Cell Carcinoma

Germany
Neurogene Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer

Solid Tumor | Advanced Solid Tumor

United States, Australia, Canada
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Metastatic... and other conditions

United States
Shyam S.D. Rao
National Cancer Institute (NCI)

Recruiting

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

Metastatic Head and Neck Squamous Cell Carcinoma | Locally Recurrent Head and Neck Squamous Cell Carcinoma | Refractory Head and Neck Squamous Cell Carcinoma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Active, not recruiting

Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer

Metastatic Lung Cancer | Stage IV Lung Cancer

United States
Xencor, Inc.
ICON Clinical Research

Completed

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)

Melanoma | Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Small Cell Lung Carcinoma | Hepatocellular Carcinoma | Fallopian Tube Cancer | Non-small Cell Lung Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Epithelial Ovarian Cancer | Intrahepatic Cholangiocarcinoma and other conditions

United States
Merck Sharp & Dohme LLC

Terminated

Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)

Advanced Solid Tumor
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm
Haider Mahdi
Mirati Therapeutics Inc.

Withdrawn

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Solid Tumors | Recurrent Endometrial Cancer

United States
Seagen Inc.

Terminated

A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

Carcinoma, Renal Cell | Breast Neoplasms | Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Carcinoma, Squamous Cell of Head and Neck | Urinary Bladder Neoplasm

United States
Iovance Biotherapeutics, Inc.

Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Melanoma | Metastatic Melanoma | Unresectable Melanoma

United States, Spain, Australia, France, Netherlands, Italy, Canada, Sweden
University of Kansas Medical Center
Merck Sharp & Dohme LLC

Active, not recruiting

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

Adenocarcinoma | Stomach Cancer | Gastro Esophageal Junction Cancer

United States
Vasgene Therapeutics, Inc

Recruiting

A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma

Metastatic Urothelial Carcinoma

United States

Search clinical trials for: Pembrolizumab, Eftilagimod alpha

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations